Module 1. Current disease-modifying therapies for relapsing MS
Please read the CE information below, then click the "Proceed" button to continue.
This activity is jointly provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.
This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Sanofi.
This activity can take up to 75 minutes to complete.
Released On: December 5, 2022
Expires On: December 5, 2023
Neurologists, primary care physicians, nurse practitioners, nurses, physician associates (PAs), rehabilitation specialists, mental health specialists, radiologists, and other clinicians who are part of the team that manages patients with MS.
At the conclusion of this activity, participants should be better able to:
- Review the mechanism of action for current therapies for the treatment of relapsing MS
- Discuss efficacy and safety data from recent clinical trials of newer MS therapies
Scott Newsome, DO, MSCS, FAAN, FANA (Development and Presenting Faculty)
Past President, Consortium of Multiple Sclerosis Centers
Director, Neurosciences Consultation and Infusion Center
Director, Johns Hopkins Neuroimmunology Clinical Fellowship Program
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Member, Miller-Coulson Academy of Clinical Excellence
Johns Hopkins University School of Medicine
Claire S. Riley, MD (Development Faculty)
Assistant Professor of Neurology
Director of the Columbia University Multiple Sclerosis Clinical Care and Research Center
Department of Neurology, Columbia University
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The CMSC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this activity for a maximum of 1.25 NCPD credit (1.25 in the area of pharmacology).
This knowledge-based activity, UAN: JA4008165-9999-22-034-H01-P, qualifies for 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.
All other healthcare professionals completing this course will be issued a statement of participation.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
Scott Newsome, DO, MSCS, FAAN, FANA
Consulting fees: Autobahn, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Greenwich Biosciences, Horizon Therapeutics, Novartis
Contracted research: Biogen, Department of Defense, Genentech/Roche, National MS Society, Patient-Centered Outcomes Research Institute
Clinical adjudication committee member: MedDay Pharmaceuticals
Lead PI: Genentech/Roche
Claire S. Riley, MD
Consulting fees: EMD Serono, Inc., TG Therapeutics
Advisor: Genentech, Janssen Scientific Affairs, LLC, Novartis Pharmaceuticals Corporation
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
How to Participate in this Activity and Obtain CE Credit
There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:
- Read the CE information
- Complete the 10-question module
- Complete the post-test and the evaluation form
A score of 80% correct must be achieved on the post-test to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful. Following the post-test and evaluation form your certificate will be made available immediately.
Our Policy On Privacy
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.
Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For questions about this activity, please contact Catamount Medical Education at firstname.lastname@example.org.